vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
Additional information regarding the composition of the Board is available in a Current Report on Form 8-K filed with the SEC.
- Additional information regarding the composition of the Board is available in a Current Report on Form 8-K filed with the SEC.
- vTv expects to use the proceeds from the PIPE to fund the first Phase 3 study of its lead product candidate, cadisegliatin, which is expected to initiate in mid-2024.
- JDRF is the world’s largest nonprofit funder of T1D research focused on accelerating cures, preventing, and treating T1D.
- There are more than 18 million people living with T1D worldwide with fewer than 30% meeting their A1c targets, demonstrating the clear need for additional therapies.